Dr Reddy Lab (Large Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Dr. Reddy's Laboratories Limited |
|||
|
Price: ₹1,288.15 (-1.09%) | ||
| 52 Week Low: ₹1,120.00 52 Week High: ₹1,421.49 |
|||
| Market Capital: 99,428.21 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Dr Reddy Lab Share Price Target For 2025
- 1.1.1: Dr Reddy Lab Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Dr Reddy Lab Share Price Target For 2026
- 1.2.1: Dr Reddy Lab Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Dr Reddy Lab Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Dr Reddy Lab Brief Company Overview
- 4: Dr Reddy Lab Financial Performance
- 4.0.1: Is Dr Reddy Lab A Good Buy For Long Term?
Dr Reddy Lab, a Large Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 125.7% returns in 5-year showing 16.5% quarterly revenue growth with 17.8% profit margin, making it a potential Multibagger.
To predict the Dr Reddy Lab's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Dr Reddy Lab Share Price Target For 2025
The line chart displays the monthly closing prices of Dr Reddy Lab with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dr Reddy Lab shares in 2025, see the table below.
Dr Reddy Lab Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1366.55 (+6.08%) | Price Action: 31 Dec 2024 Low |
| 2025 Target 2 | 1352.6 (+5%) | Price Action: 10 Jan 2025 Low |
| 2025 Target 1 | 1338.42 (+3.9%) | Price Action: 03 Oct 2024 Low |
| Current Price | 1288.15 | Dr Reddy Lab's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1265.05 (-1.8%) | Price Action: 13 Nov 2024 High |
| Stop Loss 2 | 1251.6 (-2.84%) | Price Action: 06 Nov 2024 Low |
| Stop Loss 3 | 1238.63 (-3.85%) | Price Action: 02 Jul 2024 High |
Short-Term Technical Outlook
Current Technical Position: Dr Reddy Lab is showing mixed momentum signals near key moving averages.
Key Technical Level: The 50-day moving average at ₹1285.79 serves as the nearest technical reference point.
Historical Returns: 3-month: +1.09% | 6-month: -4.59% | 1-year: +8.41%
Dr Reddy Lab Share Price Target For 2026
The line chart displays the monthly closing prices of Dr Reddy Lab with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Dr Reddy Lab shares in 2026, see the table below.
Dr Reddy Lab Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1764.27 (+36.96%) | Price Action: Chart |
| 2026 Target 2 | 1731.37 (+34.4%) | Fibonacci Extension Level 150.00% |
| 2026 Target 1 | 1690.37 (+31.22%) | Fibonacci Extension Level 64.90% |
| Current Price | 1288.15 | Dr Reddy Lab's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1195.33 (-7.21%) | Price Action: 01 Apr 2024 Low |
| Stop Loss 2 | 1183.16 (-8.16%) | Price Action: 25 Jun 2024 High |
| Stop Loss 3 | 1171.31 (-9.08%) | Price Action: 01 Dec 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: Dr Reddy Lab is currently trading at 55.8% of its 52-week range (₹1120 - ₹1421.49).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +8.41% | 3-year: +61.55% | 5-year: +125.66%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Dr Reddy Lab Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,288.15 | ||
| 2025 | ₹1,622.57 | +25.96% | ₹1,646.91 |
| 2026 | ₹1,904.88 | +17.39% | ₹1,933.45 |
| 2027 | ₹2,412.59 | +26.65% | ₹2,448.78 |
| 2028 | ₹2,657.24 | +10.14% | ₹2,697.10 |
| 2029 | ₹3,190.59 | +20.07% | ₹3,238.45 |
| 2030 | ₹3,576.24 | +12.08% | ₹3,629.88 |
| 2031 | ₹4,093.43 | +14.46% | ₹4,154.83 |
| 2032 | ₹5,096.13 | +24.49% | ₹5,172.57 |
| 2033 | ₹5,812.95 | +14.06% | ₹5,900.14 |
| 2034 | ₹6,634.51 | +14.13% | ₹6,734.03 |
| 2035 | ₹7,596.85 | +14.5% | ₹7,710.80 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Dr Reddy Lab Brief Company Overview
Dr. Reddy's Laboratories Limited: A Global Pharmaceutical Powerhouse Established in 1984, Dr. Reddy's Laboratories Limited is a global pharmaceutical leader with a presence in over 100 countries. Headquartered in Hyderabad, India, the company operates three segments:...
Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. Global Generics: Manufactures and markets prescription and over-the-counter finished pharmaceuticals under brand or generic names. PSAI: Produces active pharmaceutical ingredients, intermediates, and provides contract research services. Others: Develops oncology and inflammation therapies, differentiated formulations, and provides digital healthcare and IT support services. Dr. Reddy's is renowned for its diverse product range covering multiple therapeutic categories, including gastro-intestinal, cardiovascular, oncology, and respiratory. The company is committed to innovation, with a focus on developing affordable healthcare solutions.Dr Reddy Lab Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 99,428.21 Crore | Market valuation of Dr Reddy Lab's shares. |
| Revenue (TTM) | 29,986.7 Crore | Total revenue generated by Dr Reddy Lab over the past twelve months. |
| Net Income (TTM) | +5,333.2 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +22.51% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +17.78% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+16.5% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
-15.2% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
15.69 | Company's total debt divided by total shareholder equity. |
| Total Debt | 4,854 Crore | Sum of Dr Reddy Lab's current & long-term financial obligations. |
| Total Cash | 6,307.4 Crore | Total amount of liquid funds available to Dr Reddy Lab. |
| Beta | 0.32 | Beta is less than 1 indicating that the Dr Reddy Lab's price is less volatile than the market. |
Is Dr Reddy Lab A Good Buy For Long Term?
Dr. Reddy's Lab, a large-cap stock with a market capitalization of ₹99,428.21 crore, presents a mixed picture for long-term investment. While it boasts a substantial cash balance of ₹6,307.4 crore and a net profit of ₹5,333.2 crore (TTM), the alarming negative returns over various timeframes (e.g., -77.39% in the past 12 months, -79.07% YTD) are major concerns. The significant debt of ₹4,854 crore also needs consideration. Given these volatile performance indicators, it's currently a not a good buy for long-term investors. Further investigation into the reasons behind the substantial revenue growth (16.5% QoQ) despite profit decline (-15.2% YoY) is recommended before considering any investment.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
